122.21
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eidos Therapeutics Inc | EIDX | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 122.21 | 19:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
122.21 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
85.00 | 314.22 | 229.22 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 122.21 | USD |
Eidos Therapeutics Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 4.75B | 38.87M | 13.54M | $ 26.69M | $ - | -1.04 | -48.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Eidos Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EIDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 92.78 | 132.54 | 92.78 | 119.08 | 141,438 | 29.43 | 31.72% |
6 Months | 41.39 | 132.54 | 38.9601 | 83.14 | 184,609 | 80.82 | 195.26% |
1 Year | 47.20 | 132.54 | 28.39 | 68.02 | 136,556 | 75.01 | 158.92% |
3 Years | 20.00 | 132.54 | 8.89 | 41.59 | 154,025 | 102.21 | 511.05% |
5 Years | 20.00 | 132.54 | 8.89 | 41.59 | 154,025 | 102.21 | 511.05% |
Eidos Therapeutics Description
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. |